Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors

Overview of attention for article published in Investigational New Drugs, June 2008

Altmetric Badge

Mentioned by

patent: 10 patents

Citations

dimensions_citation: 70 Dimensions

Readers on

mendeley: 30 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 10 patents that reference this research output.

Anti-tumor agent containing immunomodulator, and antitumor effect potentiator

Grant US-11612653-B2

United States of America

Method for treating cancer patients with severe renal impairment

Grant US-10960004-B2

United States of America

Stable crystal form of tipiracil hydrochloride and crystallization method for the same

Application US-10457666-B2

United States of America

Method for treating cancer patients with severe renal impairment

Application US-10456399-B2

United States of America

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 6 additional patents.